Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group. Ruxrungtham K, et al. HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14. HIV Med. 2008. PMID: 18795960 Free article. Clinical Trial.
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, van Leeuwen R, Kunanusont C, Buranapraditkul S, Sirivichayakul S, Lange JM, Cooper DA, Phanuphak P. Kroon ED, et al. Among authors: ruxrungtham k. AIDS. 2000 Jul 7;14(10):1349-56. doi: 10.1097/00002030-200007070-00007. AIDS. 2000. PMID: 10930149 Clinical Trial.
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand.
Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, Buranapraditkun S, Techasathit W, Li Y, Emery S, Davey RT, Fosdick L, Kunanusont C, Lane HC, Phanuphak P; Vanguard Study Group. Ruxrungtham K, et al. AIDS. 2000 Nov 10;14(16):2509-13. doi: 10.1097/00002030-200011100-00013. AIDS. 2000. PMID: 11101062 Clinical Trial.
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. Ungsedhapand C, et al. Among authors: ruxrungtham k. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):116-23. doi: 10.1097/00126334-200106010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11404532 Clinical Trial.
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P. Cardiello PG, et al. Among authors: ruxrungtham k. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70. doi: 10.1097/00042560-200204150-00006. J Acquir Immune Defic Syndr. 2002. PMID: 11981362 Clinical Trial.
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P. Cardiello PG, et al. Among authors: ruxrungtham k. J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):375-9. doi: 10.1097/00126334-200304010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12640194 Clinical Trial.
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team. Ungsedhapand C, et al. Among authors: ruxrungtham k. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701. doi: 10.1097/00126334-200406010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15167288 Clinical Trial.
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Autar RS, et al. Among authors: ruxrungtham k. J Antimicrob Chemother. 2004 Oct;54(4):785-90. doi: 10.1093/jac/dkh415. Epub 2004 Aug 25. J Antimicrob Chemother. 2004. PMID: 15329366 Clinical Trial.
389 results